相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial
Robin L. Jones et al.
EUROPEAN JOURNAL OF CANCER (2021)
KITlow Cells Mediate Imatinib Resistance in Gastrointestinal Stromal Tumor
Sudeep Banerjee et al.
MOLECULAR CANCER THERAPEUTICS (2021)
Differential antitumor activity of compounds targeting the ubiquitin-proteasome machinery in gastrointestinal stromal tumor (GIST) cells
Jessica L. Rausch et al.
SCIENTIFIC REPORTS (2020)
Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor
Alfonso Garcia-Valverde et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Rhabdoid Tumors Are Sensitive to the Protein-Translation Inhibitor Homoharringtonine
Thomas P. Howard et al.
CLINICAL CANCER RESEARCH (2020)
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial
Jean-Yves Blay et al.
LANCET ONCOLOGY (2020)
Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
Cesar Serrano et al.
BRITISH JOURNAL OF CANCER (2019)
KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors-TORC1/2 Inhibition as Salvage Strategy
Thomas Muehlenberg et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Anagrelide for Gastrointestinal Stromal Tumor
Olli-Pekka Pulkka et al.
CLINICAL CANCER RESEARCH (2019)
Activated tyrosine kinases in gastrointestinal stromal tumor with loss of KIT oncoprotein expression
Yuqing Tu et al.
CELL CYCLE (2018)
A Review of Omacetaxine: A Chronic Myeloid Leukemia Treatment Resurrected
Eric S. Winer et al.
ONCOLOGY AND THERAPY (2018)
Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate
Jessica L. Rausch et al.
ONCOTARGET (2017)
IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression
Xiaoran Zhang et al.
NEURO-ONCOLOGY (2016)
CDK1 substitutes for mTOR kinase to activate mitotic cap-dependent protein translation
Masahiro Shuda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
High-throughput simultaneous screen and counterscreen identifies homoharringtonine as synthetic lethal with von Hippel-Lindau loss in renal cell carcinoma
Nicholas C. Wolff et al.
ONCOTARGET (2015)
Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells
Wei Cao et al.
SCIENTIFIC REPORTS (2015)
Unbiased Compound Screening Identifies Unexpected Drug Sensitivities and Novel Treatment Options for Gastrointestinal Stromal Tumors
Sergei Boichuk et al.
CANCER RESEARCH (2014)
Omacetaxine: A Protein Translation Inhibitor for Treatment of Chronic Myelogenous Leukemia
Varsha Gandhi et al.
CLINICAL CANCER RESEARCH (2014)
US Food and Drug Administration Approval Summary: Omacetaxine Mepesuccinate as Treatment for Chronic Myeloid Leukemia
Firoozeh Alvandi et al.
ONCOLOGIST (2014)
Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors
John Nemunaitis et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
George D. Demetri et al.
LANCET (2013)
Efficacy and Safety of Regorafenib in Patients With Metastatic and/or Unresectable GI Stromal Tumor After Failure of Imatinib and Sunitinib: A Multicenter Phase II Trial
Suzanne George et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Translation inhibitors induce cell death by multiple mechanisms and Mcl-1 reduction is only a minor contributor
L. M. Lindqvist et al.
CELL DEATH & DISEASE (2012)
The Heat Shock Protein 90 Inhibitor IPI-504 Induces KIT Degradation, Tumor Shrinkage, and Cell Proliferation Arrest in Xenograft Models of Gastrointestinal Stromal Tumors
Giuseppe Floris et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Proapoptotic Activity of Bortezomib in Gastrointestinal Stromal Tumor Cells
Sebastian Bauer et al.
CANCER RESEARCH (2010)
Kitlow Stem Cells Cause Resistance to Kit/Platelet-Derived Growth Factor α Inhibitors in Murine Gastrointestinal Stromal Tumors
Michael R. Bardsley et al.
GASTROENTEROLOGY (2010)
The Antitumor Activity of Homoharringtonine against Human Mast Cells Harboring the KIT D816V Mutation
Yanli Jin et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Homoharringtonine, Omacetaxine Mepesuccinate, and Chronic Myeloid Leukemia Circa 2009
Alfonso Quintas-Cardama et al.
CANCER (2009)
Inhibitors of Deacetylases Suppress Oncogenic KIT Signaling, Acetylate HSP90, and Induce Apoptosis in Gastrointestinal Stromal Tumors
Thomas Muehlenberg et al.
CANCER RESEARCH (2009)
Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor
Lori Rink et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Imatinib Mesylate Induces Quiescence in Gastrointestinal Stromal Tumor Cells through the CDH1-SKP2-p27Kip1 Signaling Axis
Ying Liu et al.
CANCER RESEARCH (2008)
KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway
S. Bauer et al.
ONCOGENE (2007)
Histone H2AX is a mediator of gastrointestinal stromal tumor cell apoptosis following treatment with imatinib mesylate
Ying Liu et al.
CANCER RESEARCH (2007)
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
George D. Demetri et al.
LANCET (2006)
Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor
Sebastian Bauer et al.
CANCER RESEARCH (2006)
Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies
Tommaso Caravita et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2006)
Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate
E Wardelmann et al.
CLINICAL CANCER RESEARCH (2006)
Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib
S Bauer et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation
CR Antonescu et al.
CLINICAL CANCER RESEARCH (2005)
A Multicenter phase II study of bortezomib in recurrent or metastatic sarcomas
RG Maki et al.
CANCER (2005)
Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants
M Debiec-Rychter et al.
GASTROENTEROLOGY (2005)
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial
J Verweij et al.
LANCET (2004)
Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs)
A Duensing et al.
ONCOGENE (2004)
PDGFRA activating mutations in gastrointestinal stromal tumors
MC Heinrich et al.
SCIENCE (2003)
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
GD Demetri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Conventional and molecular cytogenetic characterization of a new human cell line, GIST-T1, established from gastrointestinal stromal tumor
T Taguchi et al.
LABORATORY INVESTIGATION (2002)
STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications
DA Tuveson et al.
ONCOGENE (2001)
分享论文
